Dr. Tim Harris joined SV in 2016. He is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas.
He is a molecular biologist and biochemist. He is currently an SV Venture Partner and serves as acting EVP R&D at Bioverativ.
Before joining SV, Tim was the Senior Vice President for Precision Medicine at Biogen. Before that he served as Senior Vice President of Translational Medicine at Biogen Idec. Until 2011, Tim was Chief Technology Officer and Director of the Advanced Technology Program at SAIC-Frederick, Inc. in Maryland, which operates the National Cancer Institute’s leading center for cancer and AIDS research (currently called Frederick National Laboratory, operated by Leidos Inc.)
Tim has served as President and Chief Executive Officer of Novasite Pharmaceuticals. He founded SGX Pharmaceuticals, formerly Structural Genomics, in 1999. Tim built SGX to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly. Before founding SGX, Tim was Senior Vice President, Research and Development at Sequana/Axys. He began his scientific career working on animal viruses such as foot and mouth disease, and was one of the first molecular biologists at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993. He is currently on the Board of Directors of Opgen (NASDAQ: OPGN) and is a visiting Professor at Columbia University.
BSc, PhD, DSc – University of Birmingham England
Outside of SV
Tim currently holds a seat on the Board of Opgen (Nasdaq: OPGN) and is an observer on the Board of SMS-IC in Scotland. He is a visiting professor at Columbia University.